Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer

Gynecologic Oncology

Volumn 105, Issue 1, 2007, Pages 205-210

  Safra, Tamar ^a   Menczer, Joseph ^b   Bernstein, Rinat ^a   Shpigel, Shulem ^a   Inbar, Moshe J ^a   Grisaru, Dan ^a   Golan, Abraham ^b   Levy, Tally ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

Author keywords

Chemotherapy; Primary peritoneal; Recurrent epithelial ovarian; Topotecan

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; PLATINUM DERIVATIVE; TOPOTECAN;

ADULT; AGE DISTRIBUTION; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; EPITHELIAL CELLS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROSPECTIVE STUDIES; TOPOTECAN;

EID: 33947325163     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.11.017     Document Type: Article

References (22)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J. Clin. 56 (2006) 106-130
2. Armstrong D.K. Novel therapies in ovarian cancer management: an update on the role of topotecan. Oncologist 7 suppl 5 (2002) 1-2
3. Salzberg M., Thurlimann B., Bonnefois H., et al. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 68 (2005) 293-298
4. McGuire W.P., and Ozols R.F. Chemotherapy of advanced ovarian cancer [published erratum in Semin Oncol 1998;25:707]. Semin. Oncol. 25 (1998) 340-348
5. Hertzberg RP., Caranfa MJ., and Hecht S.M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 28 (1989) 4629-4638
6. Hsiang YH., Lihou MG., and Liu L.F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49 (1989) 5077-5082
7. Clements MK., Jones CB., Cumming M., and Daoud S.S. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother. Pharmacol. 44 (1999) 411-416
8. O'Leary J.J., Shapiro RL., Ren CJ., Chuang N., Cohen HW., and Potmesil M. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin. Cancer Res. 5 (1999) 181-187
9. ten Bokkel Huinink W., Gore M., Carmichael J., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 15 (1997) 2183-2193
10. ten Bokkel Huinink W., Carmichael J., Armstrong D., Gordon A., and Malfetano J. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. Semin. Oncol. 24 1 suppl 5 (1997) S19-S25
11. Hochster H., Liebes L., Speyer J., et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J. Clin. Oncol. 12 (1994) 553-559
12. Hochster H., Wadler S., Runowicz C., et al. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J. Clin. Oncol. 17 (1999) 2553-2561
13. Lu JM., Hochster H., Sorich J., et al. Phase I study of oxaliplatin and topotecan infusion in patients with previously treated ovarian cancer [abstract]. Proc. Am. Soc. Clin. Oncol. 22 (2003) 463 (Abstract 1860)
14. Mirchandani D., Hochster H., Hamilton A., et al. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. Clin. Cancer Res. 11 (2005) 5912-5919
15. Homesley H.D., Hall D.J., Martin D.A., et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol. Oncol. 83 (2001) 394-399
16. Levy T., Inbar M., Menczer J., Grisaru D., Glezerman M., and Safra T. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol. Oncol. 95 (2004) 686-690
17. Bhoola S.M., Coleman R.L., Herzog T., et al. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol. Oncol. 95 (2004) 564-569
18. O'Malley D.M., Azodi M., Makkenchery A., et al. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecol. Oncol. 98 (2005) 242-248
19. ten Bokkel Huinink W., Lane S.R., and Ross G.A. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann. Oncol. 15 (2004) 100-103
20. Kudelka A.P., Tresukosol D., Edwards C.L., et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J. Clin. Oncol. 14 (1996) 1552-1557
21. Herzog T.J., Powell M.A., Rader J.S., Gibb R., and Mutch D.G. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecol. Oncol. 103 (2006) 637-641
22. Bookman M.A., Malmstrom H., Bolis G., et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol. 16 (1998) 3345-3352